{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:26:07Z","timestamp":1793755567093,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The MASCC\/ISOO Clinical Practice Statement (CPS) endeavors to develop a succinct instrument for clinicians, encapsulating essential practical information requisite for the management of oral complications in oncology patients. This CPS specifically addresses the management of oral complications associated with immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This CPS was formulated through a rigorous literature review, followed by a structured discussion among a consortium of leading experts, members of the Oral Care Study Group of MASCC\/ISOO. Immunotherapeutic agents were identified utilizing PubMed, and then they were matched with the National Cancer Institute\u2019s compendium of Food and Drug Administration-approved immunotherapy drugs. The statement integrated information from the literature about the management of oral immune-related adverse events (irAEs), extrapolation from literature about the management of similar oral diseases, and the working group\u2019s clinical experience. The information is systematically presented in concise bullet points and tables, thereby creating a succinct manual delineating the optimal standard of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Oral irAEs encompass a range of mucosal and gingival conditions, dysgeusia, dysphagia, and xerostomia\/hyposalivation. The management of oral toxicities is contingent upon the severity of the symptoms. Topical steroids and immunomodulators are frequently utilized as first-line therapies for oral mucosal toxicities, and topical anesthetics are employed for pain management. Treatment strategies for dysgeusia primarily focus on symptom management. This CPS also provides a guide for oral and dental care for patients undergoing immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The management of oral toxicities induced by immunotherapy is intended to mitigate patient discomfort, enhance healing, and regain oral function. Optimal management practices necessitate a collaborative approach between medical professionals and oral health specialists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-025-09806-x","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:37:15Z","timestamp":1757745435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MASCC\/ISOO Clinical Practice Statement: management of oral complications of immunotherapy"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-7631","authenticated-orcid":false,"given":"Eduardo R.","family":"Fregnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Yarom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Raber-Durlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Shem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Elad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"9806_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis 16:223\u2013249","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"9806_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/EDBK_156572","volume":"35","author":"V Velcheti","year":"2016","unstructured":"Velcheti V, Schalper K (2016) Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book 35:298\u2013308","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"9806_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2013","unstructured":"Restifo NP, Dudley ME, Rosenberg SA (2013) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269\u2013281","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"9806_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24559","volume":"10","author":"HG Dailah","year":"2024","unstructured":"Dailah HG, Hommdi AA, Koriri MD, Algathlan EM, Mohan S (2024) Potential role of immunotherapy and targeted therapy in the treatment of cancer: a contemporary nursing practice. Heliyon 10(2). https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24559","journal-title":"Heliyon"},{"issue":"1","key":"9806_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2024","unstructured":"Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS et al (2024) Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat Rev Cancer 24(1):51\u201371","journal-title":"Nat Rev Cancer"},{"issue":"July","key":"9806_CR6","first-page":"1","volume":"14","author":"NA Beelen","year":"2023","unstructured":"Beelen NA, Aberle MR, Bruno V, Olde Damink SWM, Bos GMJ, Rensen SS et al (2023) Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Front Immunol 14(July):1\u201316","journal-title":"Front Immunol"},{"issue":"11","key":"9806_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cncr.33436","volume":"127","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wen N, Sonis ST, Villa A (2021) Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 127(11):1796\u20131804","journal-title":"Cancer"},{"issue":"6","key":"9806_CR8","first-page":"482","volume":"55","author":"S Elad","year":"2024","unstructured":"Elad S, Keegan R, Fregnani ER, Gavish L, Ottaviani G, Arany P et al (2024) Immediate pain alleviation in oral mucositis and other oral ulcerative diseases through photobiomodulation therapy: the preemptive treatment concept. Quintessence Int (Berl) 55(6):482\u2013493","journal-title":"Quintessence Int (Berl)"},{"issue":"7","key":"9806_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jdv.16464","volume":"34","author":"D Ioannides","year":"2020","unstructured":"Ioannides D, Vakirlis E, Kemeny L, Marinovic B, Massone C, Murphy R et al (2020) European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatology Venereol 34(7):1403\u20131414","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"9806_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2016.09.011","volume":"63","author":"AA Owosho","year":"2016","unstructured":"Owosho AA, Randazzo J, Rosen EB, Estilo CL, Huryn JM, Chi P et al (2016) Squamous cell carcinoma associated with chronic graft versus host disease-like\/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. Oral Oncol 63:1\u20136","journal-title":"Oral Oncol"},{"issue":"4781","key":"9806_CR11","first-page":"1","volume":"15","author":"S Elad","year":"2023","unstructured":"Elad S, Yarom N, Zadik Y (2023) Immunotherapy-related oral adverse effects: immediate sequelae, chronicity and secondary cancer. Cancer 15(4781):1\u201315","journal-title":"Cancer"},{"issue":"1","key":"9806_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/prd.12263","volume":"80","author":"S Leuci","year":"2019","unstructured":"Leuci S, Ruoppo E, Adamo D, Calabria E, Mignogna MD (2019) Oral autoimmune vesicobullous diseases: classification, clinical presentations, molecular mechanisms, diagnostic algorithms, and management. Periodontol 2000 80(1):77\u201388","journal-title":"Periodontol 2000"},{"issue":"10","key":"9806_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R et al (2022) Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatology Venereol 36(10):1689\u20131704","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"36","key":"9806_CR14","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"key":"9806_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","volume":"81","author":"S Saw","year":"2017","unstructured":"Saw S, Lee HY, Ng QS (2017) Pembrolizumab-induced Stevens\u2013Johnson syndrome in non-melanoma patients. Eur J Cancer 81:237\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.026","journal-title":"Eur J Cancer"},{"issue":"7","key":"9806_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2340\/00015555-3185","volume":"99","author":"F Miyagawa","year":"2019","unstructured":"Miyagawa F, Nakajima A, Ohyama SI, Aoki Y, Nishikawa M, Nakamura Y et al (2019) Mucosal lichen planus mimicking mucosal lesions in stevens-johnson syndrome after nivolumab therapy. Acta Derm Venereol 99(7):687\u2013688","journal-title":"Acta Derm Venereol"},{"key":"9806_CR17","doi-asserted-by":"crossref","unstructured":"Jacobsen A, Olabi B, Langley A, Beecker J, Mutter E, Shelley A et al (2022) Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome. Cochrane Database Syst Rev 3(3):CD013130.","DOI":"10.1002\/14651858.CD013130.pub2"},{"issue":"1","key":"9806_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","volume":"8","author":"ER Nadelmann","year":"2022","unstructured":"Nadelmann ER, Yeh JE, Chen ST (2022) Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol 8(1):130\u2013138","journal-title":"JAMA Oncol"},{"issue":"3","key":"9806_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ijd.16561","volume":"62","author":"C Pisano","year":"2023","unstructured":"Pisano C, Brown M, Jambusaria A (2023) A comparison of international treatment guidelines for Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Dermatol 62(3):397\u2013403","journal-title":"Int J Dermatol"},{"issue":"April","key":"9806_CR20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/JIR.S454673","volume":"17","author":"M Lin","year":"2024","unstructured":"Lin M, Gong T, Ruan S, Lv X, Chen R, Su X et al (2024) Emerging insights into Stevens-Johnson Syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy. J Inflamm Res 17(April):2337\u20132351","journal-title":"J Inflamm Res"},{"issue":"12","key":"9806_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","volume":"19","author":"JS Jacob","year":"2021","unstructured":"Jacob JS, Dutra BE, Garcia-Rodriguez V, Panneerselvam K, Abraham FO, Zou F et al (2021) Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer. JNCCN J Natl Compr Cancer Netw 19(12):1415\u20131424","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"7","key":"9806_CR22","first-page":"807","volume":"17","author":"M Lederhandler","year":"2018","unstructured":"Lederhandler M, Ho A, Brinster N, Ho R, Liebman T, Lo SK (2018) Severe oral mucositis: a rare adverse event of pembrolizumab. J Drug Dermatol 17(7):807\u2013809","journal-title":"J Drug Dermatol"},{"key":"9806_CR23","unstructured":"Anekar AA, Cascella M (2022) WHO analgesic ladder. Treasure Island (FL): Statpearls Publishing; 2022"},{"key":"9806_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08688-9","volume":"32","author":"C Hong","year":"2024","unstructured":"Hong C, Jensen SB, Vissink A, Bonomo P, Santos-Silva AR, Gueiros LA et al (2024) MASCC\/ISOO clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer 32. https:\/\/doi.org\/10.1007\/s00520-024-08688-9","journal-title":"Support Care Cancer"},{"key":"9806_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08691-0","author":"C Hong","year":"2024","unstructured":"Hong C, Epstein JB, Jensen SB, Gueiros LA, van Leeuwen SJM, Kandwal A et al (2024) MASCC\/ISOO clinical practice statement: clinical assessment of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-024-08691-0","journal-title":"Support Care Cancer"},{"issue":"9","key":"9806_CR26","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24(9):1259\u20131269","journal-title":"Oncologist"},{"issue":"2","key":"9806_CR27","first-page":"1681","volume":"30","author":"H Bustillos","year":"2022","unstructured":"Bustillos H, Indorf A, Alwan L, Thompson J, Jung L (2022) Xerostomia: an immunotherapy-related adverse effect in cancer patients. Support Care Cancer 30(2):1681\u20131687","journal-title":"Support Care Cancer"},{"key":"9806_CR28","doi-asserted-by":"publisher","unstructured":"Pasoto SG, Franco AS, Silva CA, Bonfa E (2024) Sicca syndrome\/Sj\u00f6gren's disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management. Expert Rev Clin Immunol. 2024;20(10):1149\u20131167. https:\/\/doi.org\/10.1080\/1744666X.2024.2370327","DOI":"10.1080\/1744666X.2024.2370327"},{"key":"9806_CR29","first-page":"2108","volume-title":"Contemporary oral medicine - a comprehensive approach to clinical practice","author":"S Ram","year":"2019","unstructured":"Ram S, Wada T, Sahai-Srivastava S (2019) Neurosensory disturbances including smell and taste. In: Farah CS, Balasubramaniam R, Mccullough MJ (eds) Contemporary oral medicine - a comprehensive approach to clinical practice. Springer International Publishing, pp 2108\u20132130"},{"issue":"4","key":"9806_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/lary.22490","volume":"122","author":"SM Heckmann","year":"2012","unstructured":"Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T (2012) A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope 122(4):813\u2013816","journal-title":"Laryngoscope"},{"issue":"1","key":"9806_CR31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1159\/000533373","volume":"16","author":"S Farrugia","year":"2023","unstructured":"Farrugia S, Mercieca L, Betts A, Refalo N, Boffa MJ (2023) Scleroderma secondary to pembrolizumab: a case report and review of 19 cases of anti-PD-1-induced scleroderma. Case Rep Oncol 16(1):846\u2013856","journal-title":"Case Rep Oncol"},{"issue":"1","key":"9806_CR32","first-page":"223","volume":"23","author":"S Elad","year":"2015","unstructured":"Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y et al (2015) Basic oral care for hematology\u2013oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC. Support Care Cancer 23(1):223\u2013236","journal-title":"Support Care Cancer"},{"issue":"9","key":"9806_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"X Zhou","year":"2021","unstructured":"Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X et al (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22(9):1265\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(21)00333-8","journal-title":"Lancet Oncol"},{"key":"9806_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014","journal-title":"Eur J Cancer"},{"key":"9806_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129","journal-title":"Eur J Cancer"},{"key":"9806_CR36","doi-asserted-by":"crossref","unstructured":"Ayd\u0131n AA, Top\u00e7ugil F. The potential adverse impact of post-treatment thrombocytopenia on clinical outcomes in cancer patients treated with immune checkpoint inhibitors. Cureus. 2024;16(6).","DOI":"10.7759\/cureus.62163"},{"issue":"5","key":"9806_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","volume":"71","author":"TC Haddad","year":"2022","unstructured":"Haddad TC, Zhao S, Li M, Patel SH, Johns A, Grogan M et al (2022) Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother 71(5):1157\u201365. https:\/\/doi.org\/10.1007\/s00262-021-03068-2","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"9806_CR38","doi-asserted-by":"publisher","first-page":"E963","DOI":"10.1161\/CIR.0000000000000969","volume":"143","author":"WR Wilson","year":"2021","unstructured":"Wilson WR, Gewitz M, Lockhart PB, Bolger AF, Desimone DC, Kazi DS et al (2021) Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation 143(20):E963\u2013E978","journal-title":"Circulation"},{"issue":"7","key":"9806_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","volume":"28","author":"KCJ Yuen","year":"2022","unstructured":"Yuen KCJ, Samson SL, Bancos I, Gosmanov AR, Jasim S, Fecher LA et al (2022) American Association of Clinical Endocrinology disease state clinical review: evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: a practical case-based clinical approach. Endocr Pract 28(7):719\u2013731","journal-title":"Endocr Pract"},{"issue":"August","key":"9806_CR40","first-page":"1","volume":"598","author":"KSK Ma","year":"2024","unstructured":"Ma KSK, Chiang CH, Chen ST, Dinh Y, Chiang CH, Van Dyke TE et al (2024) Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: a multi-center cohort study. Cancer Lett 598(August):1\u20136","journal-title":"Cancer Lett"},{"issue":"8","key":"9806_CR41","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/acr.20480","volume":"63","author":"A Alantar","year":"2011","unstructured":"Alantar A, Cabane J, Hachulla E, Princ G, Ginisty D, Hassin M et al (2011) Recommendations for the care of oral involvement in patients with systemic sclerosis. Arthritis Care Res 63(8):1126\u20131133","journal-title":"Arthritis Care Res"},{"issue":"5","key":"9806_CR42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/scd.12492","volume":"40","author":"FJ Alhendi","year":"2020","unstructured":"Alhendi FJ, Werth VP, Sollecito TP, Stoopler ET (2020) Systemic sclerosis: update for oral health care providers. Spec Care Dent 40(5):418\u2013430","journal-title":"Spec Care Dent"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09806-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T03:39:18Z","timestamp":1760672358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9806"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09806-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E. Fregnani, N. Blijlevens, N. Yarom, and S. Elad\u00a0reported no relevant financial or non-financial interests to disclose. A. Villa is a consultant for Merck, K\u00a0Pharmaceuticals, Afyx Therapeutics, Amgen, and Lipella Pharmaceuticals. A. Villa is Associate Editor\u00a0for Supportive Care in Cancer. J.E. Raber-Durlacher received in kind support from Thor Photomedicine\u00a0Ltd. J.B. Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, Neilsen Inc. J.B Epstein is Associate\u00a0Editor-in-Chief for Supportive Care in Cancer. P. Bossi reported participation to advisory board or\u00a0conference honoraria for Merck, Sanofi-Regeneron, Merck Sharp & Dohme, Daiichi-Sankyo, Glaxo\u00a0Smith Kline, Angelini, Nestl\u00e8, Nutricia.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MASCC\/ISOO OCSG Statements have been developed to facilitate expert-opinion-based management of oral complications of cancer and cancer therapy, where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. Statement authors and the MASCC\/ISOO do not guarantee or take responsibility for the clinical outcomes in individual patients.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"851"}}